Overview

Pharmacokinetic Study of Continuous Infusion of Remazolam in Mechanically Ventilated Patients in ICU

Status:
Active, not recruiting

Trial end date:
2022-09-01

Target enrollment:
0

Participant gender:
All

Summary

To study the pharmacokinetics of continuous infusion of remazolam in ICU mechanically ventilated critically ill patients, and the characteristics of PK in patients with liver failure; to explore whether liver failure affects the metabolism of remazolam by established population pharmacokinetics.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

The First Affiliated Hospital with Nanjing Medical University

Criteria

Inclusion Criteria:

Patients admitted to ICU for tracheal intubation and mechanical; Patients aged >18 years;
Patients with expected mechanical ventialation time >24 hours.

Exclusion Criteria:

Patients on long-term anti-anxiety medication or sleeping pills; Patients with known or
suspected hypersensitivity to remimazolam; Patients with severe central nervous system
diseases; Patients who do not wish to sign the informed consent form.